Daré Bioscience Launches First Clinically Studied Sildenafil Cream for Women
Event summary
- Daré Bioscience introduced DARE to PLAY™ Sildenafil Cream, the first topical arousal cream clinically studied for women, leveraging sildenafil as the active ingredient.
- The product is available as a Section 503B compounded product, manufactured in a cGMP-compliant facility, with prescriptions accepted in all 50 states during the pre-fulfillment period.
- Clinical studies showed the cream increases genital blood flow within 10–15 minutes, enhancing natural arousal sensations.
- Daré Bioscience is conducting a Regulation A offering to fund its mission, open to all investors.
The big picture
Daré Bioscience's launch of DARE to PLAY™ Sildenafil Cream addresses a significant gap in women’s sexual health, an area historically underfunded and underserved. The product’s clinical backing and strategic use of the 503B compounding pathway highlight the company’s focus on bringing evidence-based solutions to market while navigating regulatory hurdles. This move aligns with broader industry trends toward personalized and gender-specific healthcare innovations.
What we're watching
- Regulatory Pathway
- Whether Daré Bioscience can successfully navigate the FDA approval process for its proprietary sildenafil cream formulation while maintaining market access through the 503B compounding route.
- Market Adoption
- The pace at which healthcare providers and women adopt DARE to PLAY™, given the lack of FDA-approved therapeutics for female genital arousal challenges.
- Funding Strategy
- How Daré Bioscience's Regulation A offering performs and whether it can secure sufficient capital to advance its broader pipeline of women’s health products.
Related topics